JP2010149087A - Method for producing nanoparticle - Google Patents
Method for producing nanoparticle Download PDFInfo
- Publication number
- JP2010149087A JP2010149087A JP2008332780A JP2008332780A JP2010149087A JP 2010149087 A JP2010149087 A JP 2010149087A JP 2008332780 A JP2008332780 A JP 2008332780A JP 2008332780 A JP2008332780 A JP 2008332780A JP 2010149087 A JP2010149087 A JP 2010149087A
- Authority
- JP
- Japan
- Prior art keywords
- component
- fatty acid
- mass
- acid
- nanoparticle dispersion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 93
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 76
- 239000000194 fatty acid Substances 0.000 claims abstract description 76
- 229930195729 fatty acid Natural products 0.000 claims abstract description 76
- 239000006185 dispersion Substances 0.000 claims abstract description 58
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 56
- -1 fatty acid salt Chemical class 0.000 claims abstract description 33
- 238000002156 mixing Methods 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 239000007864 aqueous solution Substances 0.000 claims abstract description 20
- 229910052751 metal Inorganic materials 0.000 claims abstract description 18
- 239000002184 metal Substances 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003513 alkali Substances 0.000 claims description 3
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 claims description 3
- 150000001447 alkali salts Chemical class 0.000 claims description 2
- 238000000790 scattering method Methods 0.000 claims description 2
- 125000005313 fatty acid group Chemical group 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 abstract description 14
- 239000000243 solution Substances 0.000 abstract description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 30
- 238000003756 stirring Methods 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 229910052739 hydrogen Inorganic materials 0.000 description 13
- 239000001257 hydrogen Substances 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000021357 Behenic acid Nutrition 0.000 description 11
- 229940116226 behenic acid Drugs 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 7
- 229940070765 laurate Drugs 0.000 description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 235000011148 calcium chloride Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 4
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000894007 species Species 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 3
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 3
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 235000021353 Lignoceric acid Nutrition 0.000 description 2
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 235000021319 Palmitoleic acid Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940104261 taurate Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 159000000014 iron salts Chemical class 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
Abstract
Description
本発明はナノ粒子の製造方法及びそのナノ粒子に関する。 The present invention relates to a method for producing nanoparticles and the nanoparticles.
脂肪酸は、人類にとって、栄養学的にも生理学的にも非常に重要な物質である。例えば、DHA(ドコサヘキサエン酸)やEPA(エイコサペンタエン酸)は、これらを含む脂質が心血管系疾患の予防等に使用されている。また、最近では、パルミトレイン酸を含有する脂質に表皮中の抗菌性脂肪酸量を増大する作用があること(例えば、特許文献1参照)、DGLA(ジホモ−γ−リノレン酸)を含有する脂質に皮膚疾患を改善する作用があること(例えば、特許文献2参照)、またα−リノレン酸を含有する脂質に角質細胞の成熟化を促進する作用があること(例えば、特許文献3参照)がそれぞれ報告されている。そして、この様な機能を有する脂肪酸を、皮膚や毛髪や粘膜に適用する外用剤或いは経口投与剤として提供する場合、それを分散液とする手法が一般的に用いられる。 Fatty acids are very important substances for human beings, both nutritionally and physiologically. For example, lipids containing DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) are used for the prevention of cardiovascular diseases. Recently, lipids containing palmitoleic acid have the effect of increasing the amount of antibacterial fatty acids in the epidermis (see, for example, Patent Document 1), and lipids containing DGLA (dihomo-γ-linolenic acid) Reported to have an action to improve disease (for example, see Patent Document 2), and a lipid containing α-linolenic acid to promote maturation of corneocytes (for example, see Patent Document 3). Has been. And when providing the fatty acid which has such a function as an external preparation applied to skin, hair, or mucous membrane, or an oral administration agent, the method of making it into a dispersion liquid is generally used.
脂肪酸のような機能性物質を分散液とする場合、その粒径が小さいほどクリーミングや凝集を効果的に回避することができる。従って、安定した分散液を得るためには、そのナノサイズ化が有効である。このような理由から、例えば、特許文献4〜7及び非特許文献1には、機能性物質をナノサイズ化することが開示されている。 When a functional substance such as a fatty acid is used as the dispersion, creaming and aggregation can be effectively avoided as the particle size is smaller. Therefore, in order to obtain a stable dispersion, the nano-sizing is effective. For these reasons, for example, Patent Documents 4 to 7 and Non-Patent Document 1 disclose nano-size functional substances.
具体的には、特許文献4には、ポリグリセリン脂肪酸エステルを含む水溶液とトコフェロールとを200MPaという高圧で均質化処理することによりナノ粒子を得ることが開示されている。 Specifically, Patent Document 4 discloses that nanoparticles are obtained by homogenizing an aqueous solution containing a polyglycerin fatty acid ester and tocopherol at a high pressure of 200 MPa.
特許文献5には、酢酸トコフェロールに、ポリグリセリン脂肪酸エステル及びポリオキシエチレン系非イオン界面活性剤を多量に配合すると共に、グリセリンのような多価アルコールも同時に多量に配合して混合したものを水と混合することにより、高圧乳化を用いずに簡便な攪拌だけでナノ粒子を得ることが開示されている。 In Patent Document 5, a mixture of polyglycerin fatty acid ester and polyoxyethylene nonionic surfactant in a large amount of polyglycerin fatty acid ester and polyoxyethylene-based nonionic surfactant and a mixture of a large amount of polyhydric alcohol such as glycerin is mixed with water. It is disclosed that nanoparticles can be obtained by simple stirring without using high-pressure emulsification.
特許文献6には、薬物をレシチン、界面活性剤、及びエタノールと相溶させたものを水と混合することにより、高圧乳化を用いずに簡便な攪拌だけでナノ粒子を得ることが開示されている。 Patent Document 6 discloses that nanoparticles mixed with lecithin, surfactant, and ethanol are mixed with water to obtain nanoparticles by simple stirring without using high-pressure emulsification. Yes.
特許文献7には、ステアリン酸をベンゼンに溶解したものを界面活性剤液と混合し、そこに塩化カルシウム水溶液と水酸化ナトリウム水溶液とを滴下することによりステアリン酸カルシウムナノ粒子を得ることが開示されている。 Patent Document 7 discloses that calcium stearate nanoparticles are obtained by mixing stearic acid dissolved in benzene with a surfactant solution, and dropping an aqueous calcium chloride solution and an aqueous sodium hydroxide solution thereto. Yes.
非特許文献1には、亜臨界水に脂肪酸を溶解させた後、それを界面活性剤水溶液と混合しながら減圧することにより脂肪酸ナノ粒子を得ることが開示されている。
本発明の目的は、有機溶剤を用いずに安定した脂肪酸のナノ粒子分散液を簡便に調製することができるナノ粒子の製造方法及びそのナノ粒子を提供することである。 The objective of this invention is providing the manufacturing method of the nanoparticle which can prepare the nanoparticle dispersion liquid of the stable fatty acid easily without using an organic solvent, and the nanoparticle.
本発明のナノ粒子の製造方法は、有機溶剤不存在下でナノ粒子分散液を調製することによりナノ粒子を製造する方法であって、
炭素数10〜36の脂肪酸及び/又は脂肪酸塩である(A)成分の水溶液と、界面活性剤である(B)成分と、を混合する工程1と、
前記工程1で得られた液と、酸である(C)成分及び/又は2価〜3価の金属塩である(D)成分と、を混合する工程2と、
を含む。
The method for producing nanoparticles of the present invention is a method for producing nanoparticles by preparing a nanoparticle dispersion in the absence of an organic solvent,
Step 1 of mixing an aqueous solution of component (A) that is a fatty acid and / or fatty acid salt having 10 to 36 carbon atoms and component (B) that is a surfactant;
Step 2 of mixing the liquid obtained in Step 1 above with the component (C) that is an acid and / or the component (D) that is a divalent to trivalent metal salt;
including.
本発明のナノ粒子は、本発明のナノ粒子の製造方法により製造されたものである。 The nanoparticles of the present invention are produced by the method for producing nanoparticles of the present invention.
本発明によれば、工程1及び2を含む方法により有機溶剤不存在下でナノ粒子分散液を調製することで、経時安定性の劣化が抑制されると共にナノ粒子が小粒径化され、安定した脂肪酸のナノ粒子分散液を簡便に調製することができる。 According to the present invention, by preparing a nanoparticle dispersion in the absence of an organic solvent by the method including steps 1 and 2, deterioration of stability over time is suppressed, and the nanoparticles are reduced in size and stabilized. A fatty acid nanoparticle dispersion can be easily prepared.
以下、実施形態について詳細に説明する。 Hereinafter, embodiments will be described in detail.
本実施形態に係るナノ粒子の製造方法は、少なくとも下記工程1及び2を含み、有機溶剤不存在下でナノ粒子分散液を調製することによりナノ粒子を製造するものである。そして、このナノ粒子の製造方法によれば、下記工程1及び2を含む方法により有機溶剤不存在下でナノ粒子分散液を調製することで、経時安定性の劣化が抑制されると共にナノ粒子が小粒径化され、安定した脂肪酸のナノ粒子分散液を簡便に調製することができる。 The method for producing nanoparticles according to this embodiment includes at least the following steps 1 and 2, and produces nanoparticles by preparing a nanoparticle dispersion in the absence of an organic solvent. According to this method for producing nanoparticles, by preparing a nanoparticle dispersion in the absence of an organic solvent by a method comprising the following steps 1 and 2, deterioration of stability over time is suppressed and nanoparticles are produced. A stable dispersion of fatty acid nanoparticles with a reduced particle size can be easily prepared.
ここで、このナノ粒子の製造方法では有機溶剤が用いられないが、かかる有機溶剤とは、固体、気体、或いは液体を溶解することができる液体有機化合物であって、例えば、メタノール、エタノール、アセトン、プロパノール、ブタノール等が挙げられる。 Here, an organic solvent is not used in the method for producing nanoparticles, but the organic solvent is a liquid organic compound capable of dissolving a solid, a gas, or a liquid, for example, methanol, ethanol, acetone. , Propanol, butanol and the like.
(工程1)
工程1では、炭素数10〜36の脂肪酸及び/又は脂肪酸塩である(A)成分の水溶液と界面活性剤である(B)成分とを混合する。
(Process 1)
In step 1, an aqueous solution of component (A) that is a fatty acid and / or fatty acid salt having 10 to 36 carbon atoms and component (B) that is a surfactant are mixed.
(A)成分は炭素数10〜36の脂肪酸及び/又は脂肪酸塩である。 (A) A component is a C10-C36 fatty acid and / or fatty acid salt.
炭素数10〜36の脂肪酸としては、例えば、ラウリン酸(C12)、ミリスチン酸(C14)、パルミチン酸(C16)、ステアリン酸(C18)、アラキン酸(C20)、ベヘン酸(C22)、リグノセリン酸(C24)、セロチン酸(C26)、モンタン酸(C28)、パルミトレイン酸(C16)、オレイン酸(C18)、エルカ酸(C22)、リノール酸(C18)、リノレン酸(C18)、ドコサヘキサエン酸(C22)、エイコサペンタエン酸(C20)、イソステアリン酸(C18)等が挙げられる。融点が50℃以上の脂肪酸としては、例えば、ミリスチン酸、パルミチン酸、ステアリン酸、アラキン酸、ベヘン酸、リグノセリン酸、セロチン酸、モンタン酸等が挙げられる。 Examples of the fatty acid having 10 to 36 carbon atoms include lauric acid (C12), myristic acid (C14), palmitic acid (C16), stearic acid (C18), arachidic acid (C20), behenic acid (C22), and lignoceric acid. (C24), serotic acid (C26), montanic acid (C28), palmitoleic acid (C16), oleic acid (C18), erucic acid (C22), linoleic acid (C18), linolenic acid (C18), docosahexaenoic acid (C22) ), Eicosapentaenoic acid (C20), isostearic acid (C18) and the like. Examples of fatty acids having a melting point of 50 ° C. or higher include myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, serotic acid, and montanic acid.
脂肪酸塩としては、例えば、脂肪酸カリウム、脂肪酸ナトリウム、脂肪酸トリエタノールアミン、脂肪酸アンモニウム等が挙げられる。これらのうち脂肪酸カリウム、脂肪酸ナトリウムが好ましく、より粒径が小さく且つ高濃度な脂肪酸のナノ粒子を得るには脂肪酸カリウムが好ましい。 Examples of the fatty acid salt include fatty acid potassium, fatty acid sodium, fatty acid triethanolamine, and fatty acid ammonium. Of these, fatty acid potassium and sodium fatty acid are preferred, and fatty acid potassium is preferred for obtaining fatty acid nanoparticles having a smaller particle size and a higher concentration.
脂肪酸塩は、炭素数10〜36の脂肪酸をアルカリ剤により処理して得られるものであってもよい。その場合のアルカリとしては、例えば、水酸化カリウム、水酸化ナトリウム、炭酸カリウム、炭酸ナトリウム、トリエタノールアミン等が挙げられる。これらのうち水酸化カリウム、水酸化ナトリウムが好ましく、水酸化カリウムが特に好ましい。 The fatty acid salt may be obtained by treating a fatty acid having 10 to 36 carbon atoms with an alkali agent. Examples of the alkali in that case include potassium hydroxide, sodium hydroxide, potassium carbonate, sodium carbonate, triethanolamine and the like. Of these, potassium hydroxide and sodium hydroxide are preferable, and potassium hydroxide is particularly preferable.
(A)成分は、単一種又は複数種の脂肪酸だけであってもよく、また、単一種又は複数種の脂肪酸塩だけであってもよく、さらに、単一種又は複数種の脂肪酸と単一種又は複数種の脂肪酸塩との組合せであってもよい。 The component (A) may be a single type or a plurality of types of fatty acids, may be a single type or a plurality of types of fatty acid salts, and may be a single type or a plurality of types of fatty acids and a single type or It may be a combination with a plurality of types of fatty acid salts.
(A)成分の配合量は、調製されるナノ粒子分散中における含有量が0.1質量%以上となる量が好ましく、0.5質量%以上となる量がより好ましい。一方、ナノ粒子分散中における脂肪酸の含有量は飽和溶解度の量が上限となることから、(A)成分の配合量は、調製されるナノ粒子分散中における含有量が20質量%以下となる量が好ましく、10質量%以下となる量がより好ましい。なお、加温することで溶解度は高くなることから、特に融点が50℃以上の脂肪酸の場合、高濃度な脂肪酸のナノ粒子を得るには水溶液をその融点以上に加温することが好ましい。 The amount of the component (A) is preferably such that the content in the prepared nanoparticle dispersion is 0.1% by mass or more, and more preferably 0.5% by mass or more. On the other hand, since the amount of fatty acid in the nanoparticle dispersion is limited to the amount of saturated solubility, the amount of the component (A) is such that the content in the prepared nanoparticle dispersion is 20% by mass or less. Is preferable, and the amount of 10% by mass or less is more preferable. In addition, since the solubility is increased by heating, in the case of a fatty acid having a melting point of 50 ° C. or higher, the aqueous solution is preferably heated to the melting point or higher in order to obtain high-concentration fatty acid nanoparticles.
(B)成分は、(A)成分以外の界面活性剤である。 The component (B) is a surfactant other than the component (A).
界面活性剤は、脂肪酸をナノサイズで分散させる観点から、非イオン界面活性剤、陰イオン界面活性剤、両性イオン界面活性剤が好ましい。具体的には、例えば、非イオン活性剤としては、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンソルビタン脂肪酸エステル等が挙げられる。陰イオン活性剤としては、例えば、ポリオキシエチレンアルキルエーテル硫酸塩、ポリオキシエチレンアルキル酢酸塩、ポリオキシエチレンアルキルエーテルリン酸塩、N-アシルタウリン塩、N-アシルアミノ酸塩等が挙げられる。両性イオン活性剤としては、例えば、アルキルベタイン、アミンオキサイド、イミダゾリニウムベタイン、酵素分解レシチン等が挙げられる。これらのうちアルキル鎖長が炭素数12であるものが特に好ましい。 The surfactant is preferably a nonionic surfactant, an anionic surfactant, or an amphoteric surfactant from the viewpoint of dispersing the fatty acid in nano size. Specifically, examples of the nonionic active agent include polyglycerin fatty acid ester, sucrose fatty acid ester, polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester and the like. Examples of the anionic activator include polyoxyethylene alkyl ether sulfate, polyoxyethylene alkyl acetate, polyoxyethylene alkyl ether phosphate, N-acyl taurine salt, N-acyl amino acid salt and the like. Examples of zwitterionic activators include alkyl betaines, amine oxides, imidazolinium betaines, and enzymatically decomposed lecithins. Of these, those having an alkyl chain length of 12 carbon atoms are particularly preferred.
界面活性剤は、単一種又は複数種の非イオン界面活性剤だけであってもよく、また、単一種又は複数種の陰イオン界面活性剤だけであってもよく、また、単一種又は複数種の両性イオン界面活性剤だけであってもよく、さらに、これらの組合せであってもよい。 The surfactant may be only one or a plurality of nonionic surfactants, may be only a single species or a plurality of anionic surfactants, and may be a single species or a plurality of species. These zwitterionic surfactants may be used alone, or a combination thereof.
界面活性剤の配合量は、(A)成分に対する(B)成分の質量比率が(B)成分の質量/(A)成分の質量=0.1〜5.0となる量が好ましく、0.5〜3.0となる量がより好ましい。 The blending amount of the surfactant is preferably such that the mass ratio of the (B) component to the (A) component is such that the mass of the (B) component / the mass of the (A) component = 0.1 to 5.0. An amount of 5 to 3.0 is more preferable.
(A)成分の水溶液と(B)成分との混合手段としては、特に限定されるものではなく、例えば、プロペラ、タービン、ディスパー、アンカーなどの攪拌翼やスターラー等の公知の攪拌手段が挙げられる。混合温度は、(A)成分の融点以上が好ましく、例えば、40〜100℃であることが好ましく、50〜90℃であることがより好ましい。 The mixing means of the aqueous solution of component (A) and the component (B) is not particularly limited, and examples thereof include known stirring means such as stirring blades such as a propeller, turbine, disper, and anchor, and a stirrer. . The mixing temperature is preferably equal to or higher than the melting point of the component (A), for example, preferably 40 to 100 ° C, and more preferably 50 to 90 ° C.
この工程1では、脂肪酸の粒径を小さくする観点から、分散(A)成分の水溶液と(B)成分との混合温度を、(A)成分の融点又は40℃を超える温度のいずれか高い温度とし、それらを混合した液を20〜40℃まで急冷却することが好ましい。その場合、冷却手段としては、特に限定されるものではなく、例えば、二重管向流式冷却装置等を用いた公知の方法が挙げられる。冷却速度は、5℃/秒以上であることが好ましく、10℃/秒以上であることがより好ましい。 In this step 1, from the viewpoint of reducing the particle size of the fatty acid, the mixing temperature of the aqueous solution of the component (A) and the component (B) is the higher of the melting point of the component (A) or the temperature exceeding 40 ° C. It is preferable to rapidly cool the liquid obtained by mixing them to 20 to 40 ° C. In that case, the cooling means is not particularly limited, and for example, a known method using a double-tube countercurrent cooling device or the like can be used. The cooling rate is preferably 5 ° C./second or more, and more preferably 10 ° C./second or more.
なお、この工程1において、(A)成分及び(B)成分の他、増粘剤、防腐剤、着色剤、崩壊防止剤、酸化防止剤等を混合してもよい。 In addition, in this process 1, you may mix a thickener, antiseptic | preservative, a coloring agent, a disintegration inhibitor, antioxidant, etc. other than (A) component and (B) component.
(工程2)
工程2では、工程1で得られた液と酸である(C)成分及び/又は2価〜3価の金属塩である(D)成分とを混合する。これにより脂肪酸のナノ粒子分散液が生成する。
(Process 2)
In Step 2, the liquid obtained in Step 1 is mixed with the component (C) that is an acid and / or the component (D) that is a divalent to trivalent metal salt. This produces a nanoparticle dispersion of the fatty acid.
(C)成分は酸である。 Component (C) is an acid.
酸としては、例えば、塩酸、硫酸、硝酸、リン酸、クエン酸、乳酸、リンゴ酸、フマル酸、コハク酸等が挙げられる。なかでも、塩酸、クエン酸が好ましい。 Examples of the acid include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, citric acid, lactic acid, malic acid, fumaric acid, succinic acid and the like. Of these, hydrochloric acid and citric acid are preferable.
(C)成分は、単一種だけであってもよく、また、複数種であってもよい。(C)成分のみを配合する場合、その配合量は、ナノ粒子分散液の安定性の観点から、(C)成分が有する酸性水素モル数/(A)成分のモル数=0.8〜3となる量が好ましく、0.9〜1.5となる量がより好ましい。 Component (C) may be a single species or a plurality of species. When blending only the component (C), the blending amount is from the viewpoint of the stability of the nanoparticle dispersion, the number of moles of acidic hydrogen in the component (C) / the number of moles of the component (A) = 0.8-3. An amount that becomes 0.9 to 1.5 is more preferable.
(D)成分は2価〜3価の金属塩である。 Component (D) is a divalent to trivalent metal salt.
2価の金属塩としては、例えば、塩化カルシウム、乳酸カルシウム、硫酸カルシウムなどのカルシウム塩;塩化亜鉛、酢酸亜鉛、硫酸亜鉛などの亜鉛塩;塩化銅、硫酸銅などの銅塩等が挙げられる。3価の金属塩としては、塩化鉄、硫酸鉄などの鉄塩等が挙げられる。これらのうち塩化カルシウム、乳酸カルシウム、塩化亜鉛が好ましい。 Examples of the divalent metal salt include calcium salts such as calcium chloride, calcium lactate and calcium sulfate; zinc salts such as zinc chloride, zinc acetate and zinc sulfate; copper salts such as copper chloride and copper sulfate. Examples of the trivalent metal salt include iron salts such as iron chloride and iron sulfate. Of these, calcium chloride, calcium lactate and zinc chloride are preferred.
(D)成分は、単一種又は複数種の2価の金属塩だけであってもよく、また、単一種又は複数種の3価の金属塩だけであってもよく、さらに、単一種又は複数種の2価の金属塩と単一種又は複数種の3価の金属塩との組合せであってもよい。 The component (D) may be only a single species or a plurality of types of divalent metal salts, may be a single species or a plurality of types of trivalent metal salts, and may be a single species or a plurality of species. A combination of a divalent metal salt of a species and a single species or a plurality of trivalent metal salts may be used.
(D)成分のみを配合する場合、その配合量は、ナノ粒子分散液の安定性の観点から、2価の金属塩では、(D)成分が有する金属モル数/(A)成分のモル数=0.4〜1.5となる量が好ましく、0.45〜0.75となる量がより好ましく、また、3価の金属塩では、(D)成分が有する金属モル数/(A)成分のモル数=0.27〜1.0となる量が好ましく、0.3〜0.5となる量がより好ましい。 When blending only the component (D), the blending amount is the number of moles of the metal (D) component / number of moles of the component (A) in the case of a divalent metal salt from the viewpoint of the stability of the nanoparticle dispersion. = 0.4 to 1.5 is preferable, and an amount of 0.45 to 0.75 is more preferable. In the case of a trivalent metal salt, the number of moles of metal contained in the component (D) / (A) The amount of the number of moles of the component = 0.27 to 1.0 is preferable, and the amount of 0.3 to 0.5 is more preferable.
(C)成分及び(D)成分は、いずれか一方だけであってもよく、また、それらの両方であってもよい。 Only one of the component (C) and the component (D) may be used, or both of them may be used.
工程1で得られた液と(C)成分及び/又は(D)成分との混合手段としては、特に限定されるものではなく、例えば、プロペラ、タービン、ディスパー、アンカーなどの攪拌翼やスターラーを備えた静置型混合器やマイクロミキサー等の公知の手段が挙げられる。混合温度は、例えば、20〜40℃であることが好ましく、25〜35℃であることがより好ましい。工程1において液を20〜40℃まで急冷却した場合、液が不安定となっていることから、急冷直後に(C)成分及び/又は(D)成分を混合することが好ましい。 The mixing means of the liquid obtained in step 1 and the component (C) and / or the component (D) is not particularly limited. For example, a stirring blade or a stirrer such as a propeller, a turbine, a disper, or an anchor is used. Well-known means such as a stationary mixer and a micromixer provided can be used. For example, the mixing temperature is preferably 20 to 40 ° C, and more preferably 25 to 35 ° C. When the liquid is rapidly cooled to 20 to 40 ° C. in Step 1, since the liquid becomes unstable, it is preferable to mix the component (C) and / or the component (D) immediately after the rapid cooling.
なお、この工程2において、(C)成分及び/又は(D)成分の他、増粘剤、防腐剤、着色剤、崩壊防止剤、酸化防止剤等を混合してもよい。 In Step 2, in addition to the component (C) and / or the component (D), a thickener, an antiseptic, a colorant, an anti-collapse agent, an antioxidant, and the like may be mixed.
(工程3)
本実施形態に係るナノ粒子の製造方法では、工程2において(D)成分を混合した場合、工程3として、工程2で得られた液(ナノ粒子分散液)と1価〜3価の塩基性塩である(E)成分とを混合してもよい。
(Process 3)
In the method for producing nanoparticles according to the present embodiment, when the component (D) is mixed in Step 2, as Step 3, the liquid (nanoparticle dispersion) obtained in Step 2 and monovalent to trivalent basicity are used. You may mix the (E) component which is a salt.
(E)成分は1価〜3価の塩基性塩である。 The component (E) is a monovalent to trivalent basic salt.
(E)成分としては、例えば、炭酸水素ナトリウム、炭酸水素カリウムなどの炭酸水素塩;リン酸水素ナトリウム、リン酸水素カリウムなどのリン酸水素塩;炭酸ナトリウム、炭酸カリウムなどの炭酸塩;リン酸ナトリウム、リン酸カリウムなどのリン酸塩等が挙げられる。これらのうち炭酸塩及びリン酸塩が好ましい。 Examples of the component (E) include hydrogen carbonates such as sodium hydrogen carbonate and potassium hydrogen carbonate; hydrogen phosphates such as sodium hydrogen phosphate and potassium hydrogen phosphate; carbonates such as sodium carbonate and potassium carbonate; Examples thereof include phosphates such as sodium and potassium phosphate. Of these, carbonates and phosphates are preferred.
(E)成分の配合量は、ナノ粒子分散液の安定性の観点から、(E)成分のモル数/(D)成分のモル数=0.05〜0.5となる量が好ましく、0.1〜0.3となる量がより好ましい。 The amount of component (E) is preferably such that the number of moles of component (E) / number of moles of component (D) = 0.05 to 0.5, from the viewpoint of the stability of the nanoparticle dispersion. An amount of 0.1 to 0.3 is more preferable.
工程2で得られた液と(E)成分との混合手段としては、特に限定されるものではなく、例えば、プロペラ、タービン、ディスパー、アンカーなどの攪拌翼やスターラーを備えた静置型混合器やマイクロミキサー等の公知の手段が挙げられる。混合温度は、例えば、20〜40℃であることが好ましく、25〜35℃であることがより好ましい。 The mixing means of the liquid obtained in step 2 and the component (E) is not particularly limited. For example, a stationary mixer equipped with a stirring blade or a stirrer such as a propeller, a turbine, a disper, or an anchor, Well-known means, such as a micro mixer, are mentioned. For example, the mixing temperature is preferably 20 to 40 ° C, and more preferably 25 to 35 ° C.
なお、この工程3において、(E)成分の他、増粘剤、防腐剤、着色剤、崩壊防止剤、酸化防止剤等を混合してもよい。 In Step 3, in addition to the component (E), a thickener, an antiseptic, a colorant, a disintegration inhibitor, an antioxidant, and the like may be mixed.
(ナノ粒子分散液)
以上の工程を経て調製されるナノ粒子分散液は、脂肪酸のナノ粒子の濃度が0.1〜20質量%であることが好ましく、0.5〜10質量%であることが好ましい。これは、工程1における(A)成分の配合量の設定により制御することができる。
(Nanoparticle dispersion)
The nanoparticle dispersion prepared through the above steps preferably has a fatty acid nanoparticle concentration of 0.1 to 20% by mass, preferably 0.5 to 10% by mass. This can be controlled by setting the amount of component (A) in step 1.
ナノ粒子分散液は、ナノ粒子の動的散乱法により測定される動的散乱径が1〜250nmであることが好ましく、5〜200nmであることがより好ましい。これは、(A)成分の種類、(B)成分の種類と量、(C)成分及び/又は(D)成分の配合量により制御することができる。より微細なナノ粒子を得るには、(B)成分である界面活性剤の種類をアルキル鎖が炭素数12のものを多く配合することが好ましい。 The nanoparticle dispersion liquid preferably has a dynamic scattering diameter measured by a dynamic scattering method of nanoparticles of 1 to 250 nm, and more preferably 5 to 200 nm. This can be controlled by the type of component (A), the type and amount of component (B), the amount of component (C) and / or component (D). In order to obtain finer nanoparticles, it is preferable that the surfactant (B) component contains a large number of surfactants having 12 alkyl chains.
ナノ粒子分散液は、製剤用組成物として含有する製品として、例えば、皮膚や毛髪や粘膜に適用する化粧品、石鹸、ボディーソープ、洗顔剤、入浴剤、化粧水、ローション、シャンプー、リンス、歯磨き剤、デンタルリンス、パップ剤、貼付け剤などの外用剤;経口投与剤等が挙げられる。 Nanoparticle dispersions are products that can be used as pharmaceutical compositions, such as cosmetics, soaps, body soaps, facial cleansers, bath preparations, lotions, lotions, shampoos, rinses, and toothpastes that are applied to skin, hair and mucous membranes. , Dental rinses, poultices, adhesives and other external preparations; oral administration agents and the like.
(分散液調製)
以下の実施例1〜13並びに比較例1〜2の分散液を調製した。なお、それぞれの構成については表1にも示す。
(Dispersion preparation)
Dispersions of the following Examples 1 to 13 and Comparative Examples 1 and 2 were prepared. Each configuration is also shown in Table 1.
<実施例1>
イオン交換水37.8gにスターラーピースを用いて攪拌しながら(A)成分としてベヘン酸含有脂肪酸(花王社製 商品名:ルナックBA、ベヘン酸85質量%含有、中和価=166)1.0g及び水酸化カリウム0.157gを加えて85℃で30分間攪拌混合した。次に、この水溶液に攪拌を継続しながら(B)成分としてデカグリセリンラウリン酸エステル(三菱化学フーズ社製 商品名:リョートーポリグリエステルL−7D、HLB=17)1.0gを加えて3分間攪拌混合した。そして、この水溶液に攪拌を継続しながら(C)成分として0.31Nの塩酸10.0gを加えて直ぐに二重管向流式冷却装置により通過時間5秒で85℃から室温(25℃)まで急冷却し、脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例1とした。実施例1のpHは2であった。pHは、pHメーター(堀場製作所製 型番:D−53)を用いて25℃において測定した(実施例2以下同様)。
<Example 1>
1.0g of behenic acid-containing fatty acid (trade name: LUNAC BA, 85% by mass of behenic acid, neutralization value = 166, manufactured by Kao Corporation) as component (A) while stirring with 37.8g of ion-exchanged water using a stirrer piece Then, 0.157 g of potassium hydroxide was added and the mixture was stirred and mixed at 85 ° C. for 30 minutes. Next, while continuing stirring to this aqueous solution, 1.0 g of decaglycerin lauric acid ester (trade name: Ryoto Polyglycerin L-7D, HLB = 17, manufactured by Mitsubishi Chemical Foods Co., Ltd.) was added as component (B) for 3 minutes. Stir and mix. Then, while continuing stirring to this aqueous solution, 10.0 g of 0.31N hydrochloric acid was added as component (C), and immediately from 85 ° C. to room temperature (25 ° C.) in a passage time of 5 seconds by a double tube countercurrent cooling device. The solution was rapidly cooled to obtain a dispersion of fatty acid nanoparticles. This nanoparticle dispersion was designated as Example 1. The pH of Example 1 was 2. The pH was measured at 25 ° C. using a pH meter (manufactured by HORIBA, Ltd., model number: D-53) (same as Example 2 and the following).
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例2>
イオン交換水37.8gにスターラーピースを用いて攪拌しながら(A)成分としてベヘン酸含有脂肪酸(花王社製 商品名:ルナックBA、ベヘン酸85質量%含有、中和価=166)1.0g及び水酸化カリウム0.157gを加えて85℃で30分間攪拌混合した。次に、この水溶液に攪拌を継続しながら(B)成分としてデカグリセリンラウリン酸エステル(三菱化学フーズ社製 商品名:リョートーポリグリエステルL−7D、HLB=17)1.0gを加えて3分間攪拌混合して直ぐに二重管向流式冷却装置により通過時間5秒で85℃から室温(25℃)まで急冷却した。そして、この水溶液に攪拌を継続しながら(C)成分として0.31Nの塩酸10.0gを加え、脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例2とした。実施例2のpHは1.8であった。
<Example 2>
1.0g of behenic acid-containing fatty acid (trade name: LUNAC BA, 85% by mass of behenic acid, neutralization value = 166, manufactured by Kao Corporation) as component (A) while stirring with 37.8g of ion-exchanged water using a stirrer piece Then, 0.157 g of potassium hydroxide was added and mixed with stirring at 85 ° C. for 30 minutes. Next, while continuing stirring to this aqueous solution, 1.0 g of decaglycerin lauric acid ester (trade name: Ryoto Polyglycerin L-7D, HLB = 17, manufactured by Mitsubishi Chemical Foods Co., Ltd.) was added as component (B) for 3 minutes. Immediately after stirring and mixing, the mixture was rapidly cooled from 85 ° C. to room temperature (25 ° C.) with a passage time of 5 seconds using a double-tube countercurrent cooling device. And while continuing stirring to this aqueous solution, 10.0 g of 0.31N hydrochloric acid was added as (C) component, and the nanoparticle dispersion liquid of the fatty acid was obtained. This nanoparticle dispersion was designated as Example 2. The pH of Example 2 was 1.8.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例3>
イオン交換水の量を38.3g及びデカグリセリンラウリン酸エステルの量を0.5gとしたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例3とした。実施例3のpHは2.3であった。
<Example 3>
A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that the amount of ion-exchanged water was 38.3 g and the amount of decaglycerin laurate was 0.5 g. This nanoparticle dispersion was designated as Example 3. The pH of Example 3 was 2.3.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=0.50である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the (B) component to the (A) component is the mass of the (B) component / the mass of the (A) component = 0.50. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例4>
イオン交換水の量を35.8g及びデカグリセリンラウリン酸エステルの量を3.0gとしたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例4とした。実施例4のpHは2.2であった。
<Example 4>
A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that the amount of ion-exchanged water was 35.8 g and the amount of decaglycerin laurate was 3.0 g. This nanoparticle dispersion was designated as Example 4. The pH of Example 4 was 2.2.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=3.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the (B) component to the (A) component is (B) component mass / (A) component mass = 3.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例5>
デカグリセリンラウリン酸エステルを加えた後に11℃まで急冷却したことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例5とした。実施例5のpHは2.1であった。
<Example 5>
A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that decaglycerin laurate was added and then rapidly cooled to 11 ° C. This nanoparticle dispersion was designated as Example 5. The pH of Example 5 was 2.1.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例6>
(B)成分としてデカグリセリンラウリン酸エステルの代わりにショ糖ラウリン酸エステル(三菱化学フーズ社製 商品名:リョートーシュガーエステルL−1695、HLB=16)を用いたこと、0.31Nの塩酸を9.5g用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例6とした。実施例6のpHは4.8であった。
<Example 6>
(B) Instead of decaglycerin laurate as a component, sucrose laurate (trade name: Ryoto Sugar Ester L-1695, HLB = 16, manufactured by Mitsubishi Chemical Foods) was used, and 0.31N hydrochloric acid was used. A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that 9.5 g was used. This nanoparticle dispersion was designated as Example 6. The pH of Example 6 was 4.8.
なお、(A)成分の濃度は2.02質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=0.95である。 In addition, the density | concentration of (A) component is 2.02 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 0.95.
<実施例7>
イオン交換水の量を33.5g、ベヘン酸の量を3.0g、水酸化カリウムの量を0.457g、及びデカグリセリンラウリン酸エステルの量を3.0g、中和に0.93N塩酸10.0gを用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例7とした。実施例7のpHは2.2であった。
<Example 7>
The amount of ion-exchanged water is 33.5 g, the amount of behenic acid is 3.0 g, the amount of potassium hydroxide is 0.457 g, the amount of decaglycerin laurate is 3.0 g, and 0.93N hydrochloric acid is used for neutralization. A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that 0.0 g was used. This nanoparticle dispersion was designated as Example 7. The pH of Example 7 was 2.2.
なお、(A)成分の濃度は6.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 6.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例8>
イオン交換水の量を37.9gとし、水酸化カリウムの代わりに水酸化ナトリウム0.106gを用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例8とした。実施例8のpHは1.8であった。
<Example 8>
A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that the amount of ion-exchanged water was 37.9 g, and 0.106 g of sodium hydroxide was used instead of potassium hydroxide. This nanoparticle dispersion was designated as Example 8. The pH of Example 8 was 1.8.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例9>
(C)成分として塩酸の代わりに0.10Nクエン酸水溶液を用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例9とした。実施例9のpHは5.3であった。
<Example 9>
A fatty acid nanoparticle dispersion was obtained in the same manner as in Example 2 except that a 0.10N aqueous citric acid solution was used as the component (C) instead of hydrochloric acid. This nanoparticle dispersion was designated as Example 9. The pH of Example 9 was 5.3.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=0.96である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 0.96.
<実施例10>
水酸化カリウムの量を0.166gとし、(C)成分の塩酸の代わりに(D)成分として0.31N塩化カルシウム水溶液5.0gを用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例10とした。実施例10のpHは5.3であった。
<Example 10>
The amount of potassium hydroxide was 0.166 g, and the fatty acid solution was the same as in Example 2 except that 5.0 g of a 0.31N calcium chloride aqueous solution was used as the component (D) instead of hydrochloric acid as the component (C). A nanoparticle dispersion was obtained. This nanoparticle dispersion was designated as Example 10. The pH of Example 10 was 5.3.
なお、(A)成分の濃度は2.22質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(D)成分が有する金属モル数/(A)成分のモル数=0.50である。 In addition, the density | concentration of (A) component is 2.22 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of metal in component (D) / number of moles of component (A) = 0.50.
<実施例11>
(B)成分としてデカグリセリンラウリン酸エステルの代わりにN−ラウロイルメチルタウリンナトリウム(日光ケミカルズ社製 商品名:NIKKO LMT)を用いたことを除いて実施例2と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例11とした。実施例11のpHは2.3であった。
<Example 11>
(B) Nanoparticle dispersion of fatty acid in the same manner as in Example 2, except that sodium N-lauroylmethyl taurate (trade name: NIKKO LMT manufactured by Nikko Chemicals) was used in place of decaglycerin laurate. Got. This nanoparticle dispersion was designated as Example 11. The pH of Example 11 was 2.3.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<実施例12>
(B)成分としてデカグリセリンラウリン酸エステルの代わりにN−ラウロイルメチルタウリンナトリウム(日光ケミカルズ社製 商品名:NIKKO LMT)を用いたことを除いて実施例10と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例12とした。実施例12のpHは6.9であった。
<Example 12>
(B) Nanoparticle dispersion of fatty acid in the same manner as in Example 10 except that sodium N-lauroylmethyl taurate (trade name: NIKKO LMT manufactured by Nikko Chemicals Co., Ltd.) was used in place of decaglycerin laurate Got. This nanoparticle dispersion was designated as Example 12. The pH of Example 12 was 6.9.
なお、(A)成分の濃度は2.22質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(D)成分が有する金属モル数/(A)成分のモル数=0.5である。 In addition, the density | concentration of (A) component is 2.22 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of metal in component (D) / number of moles of component (A) = 0.5.
<実施例13>
(D)成分の0.31N塩化カルシウム水溶液を加えた後、さらに攪拌を継続しながら(E)成分として0.31N炭酸ナトリウム水溶液1.25gを加えて60分間攪拌混合したことを除いて実施例12と同様にして脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を実施例13とした。実施例13のpHは10.5であった。
<Example 13>
Example: Except for adding 0.31N calcium chloride aqueous solution as component (D) and then adding 1.25 g of 0.31N sodium carbonate aqueous solution as component (E) and stirring for 60 minutes while continuing stirring. In the same manner as in Example 12, a fatty acid nanoparticle dispersion was obtained. This nanoparticle dispersion was designated as Example 13. The pH of Example 13 was 10.5.
なお、(A)成分の濃度は2.16質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(D)成分が有する金属モル数/(A)成分のモル数=0.50である。(E)成分のモル数/(D)成分のモル数=0.25である。 In addition, the density | concentration of (A) component is 2.16 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of metal in component (D) / number of moles of component (A) = 0.50. The number of moles of component (E) / number of moles of component (D) = 0.25.
<比較例1>
イオン交換水378.0gにスターラーピースを用いて攪拌しながら水酸化カリウム1.57g、(C)成分として0.31Nの塩酸100.0gを加えて85℃で5分間攪拌混合した。次に、この水溶液に攪拌を継続しながら(A)成分としてベヘン酸含有脂肪酸(花王社製 商品名:ルナックBA、ベヘン酸85質量%含有、中和価=166)10.0gを加えて3分間攪拌混合した。そして、この水溶液をTKホモミキサー(プライミックス社製)を用いて8000rpmで1分間攪拌して直ぐに二重管向流式冷却装置により通過時間5秒で85℃から室温(25℃)まで急冷却し、脂肪酸の分散液を得た。この分散液を比較例1とした。
<Comparative Example 1>
While stirring with 378.0 g of ion-exchanged water using a stirrer piece, 1.57 g of potassium hydroxide and 100.0 g of 0.31N hydrochloric acid as component (C) were added and stirred and mixed at 85 ° C. for 5 minutes. Next, 10.0 g of a behenic acid-containing fatty acid (trade name: Lunac BA, 85% by weight of behenic acid, neutralization value = 166) was added as component (A) while continuing to stir the aqueous solution. Stir and mix for a minute. This aqueous solution was stirred at 8000 rpm for 1 minute using a TK homomixer (manufactured by Primix) and immediately cooled rapidly from 85 ° C. to room temperature (25 ° C.) with a double tube countercurrent cooling device in 5 seconds. A fatty acid dispersion was obtained. This dispersion was designated as Comparative Example 1.
なお、(A)成分の濃度は1.95質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 1.95 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
<比較例2>
イオン交換水29.8gにスターラーピースを用いて攪拌しながら(A)成分としてベヘン酸含有脂肪酸(花王社製 商品名:ルナックBA、ベヘン酸85質量%含有、中和価=166)1.0g及び水酸化カリウム0.157gを加えて85℃で30分間攪拌混合した。次に、この水溶液に攪拌を継続しながら(B)成分としてデカグリセリンラウリン酸エステル(三菱化学フーズ社製 商品名:リョートーポリグリエステルL−7D、HLB=17)1.0gを加えて3分間攪拌混合した。本液を70℃まで冷却した後、スターラーピースを用いて攪拌しながら8.0gのエタノールを加え、3分間攪拌混合して直ぐに二重管向流式冷却装置により通過時間5秒で70℃から室温(25℃)まで急冷却した。そして、この水溶液に攪拌を継続しながら(C)成分として0.31Nの塩酸10.0gを加え、脂肪酸のナノ粒子分散液を得た。このナノ粒子分散液を比較例2とした。比較例2のpHは2.0であった。
<Comparative example 2>
While stirring with 29.8 g of ion-exchanged water using a stirrer piece, behenic acid-containing fatty acid (product name: Lunac BA, containing 85% by mass of behenic acid, neutralization value = 166) as component (A) 1.0 g Then, 0.157 g of potassium hydroxide was added and the mixture was stirred and mixed at 85 ° C. for 30 minutes. Next, while continuing stirring to this aqueous solution, 1.0 g of decaglycerin lauric acid ester (trade name: Ryoto Polyglycerin L-7D, HLB = 17, manufactured by Mitsubishi Chemical Foods Co., Ltd.) was added as component (B) for 3 minutes. Stir and mix. After cooling this solution to 70 ° C., 8.0 g of ethanol was added with stirring using a stirrer piece, and the mixture was stirred and mixed for 3 minutes. It was cooled rapidly to room temperature (25 ° C.). Then, while continuing stirring to this aqueous solution, 10.0 g of 0.31N hydrochloric acid was added as component (C) to obtain a nanoparticle dispersion of fatty acid. This nanoparticle dispersion was designated as Comparative Example 2. The pH of Comparative Example 2 was 2.0.
なお、(A)成分の濃度は2.00質量%である。(A)成分に対する(B)成分の質量比率は(B)成分の質量/(A)成分の質量=1.00である。(C)成分が有する酸性水素モル数/(A)成分のモル数=1.0である。 In addition, the density | concentration of (A) component is 2.00 mass%. The mass ratio of the component (B) to the component (A) is the mass of the component (B) / the mass of the component (A) = 1.00. The number of moles of acidic hydrogen contained in component (C) / number of moles of component (A) = 1.0.
(試験評価方法)
<動的散乱径>
実施例1〜13及び比較例1〜2のそれぞれについて、動的散乱粒度分布測定装置(大塚電子社製 型番:DLS−Z2)を用いて動的散乱径を測定した。
(Test evaluation method)
<Dynamic scattering diameter>
About each of Examples 1-13 and Comparative Examples 1-2, the dynamic scattering diameter was measured using the dynamic scattering particle size distribution measuring apparatus (Otsuka Electronics Co., Ltd. model number: DLS-Z2).
<液安定性>
実施例1〜13及び比較例1〜2のそれぞれについて、作製当初から12時間後の外観を目視にて評価した。
<Liquid stability>
About each of Examples 1-13 and Comparative Examples 1-2, the external appearance 12 hours after the manufacture was visually evaluated.
(試験評価結果)
試験結果を表1に示す。
(Test evaluation results)
The test results are shown in Table 1.
動的散乱径は、実施例1が160nm、実施例2が38nm、実施例3が76nm、実施例4が20nm、実施例5が90nm、実施例6が38nm、実施例7が45nm、実施例8が45nm、実施例9が29nm、実施例10が71nm、実施例11が18nm、実施例12が18nm、及び実施例13が17nm、並びに、比較例1が1500nm、及び比較例2が354nmであった。 The dynamic scattering diameter is 160 nm for Example 1, 38 nm for Example 2, 76 nm for Example 3, 20 nm for Example 4, 90 nm for Example 5, 38 nm for Example 6, 45 nm for Example 7, and Example. 8 is 45 nm, Example 9 is 29 nm, Example 10 is 71 nm, Example 11 is 18 nm, Example 12 is 18 nm, Example 13 is 17 nm, Comparative Example 1 is 1500 nm, and Comparative Example 2 is 354 nm. there were.
液安定性は、実施例1〜13では、いずれも作製当初から12時間後まで青白く透明な外観を保って安定であったのに対し、比較例1では、作製当初から白濁しており、12時間後には液面にクリーミングが確認され、比較例2では、作製当初から白濁しており、12時間後も白濁のままであった。 In Examples 1 to 13, the liquid stability was stable while maintaining a bluish and transparent appearance until 12 hours from the beginning of production, whereas in Comparative Example 1, the liquid stability was cloudy from the beginning of production. After a time, creaming was confirmed on the liquid surface, and in Comparative Example 2, it was cloudy from the beginning of production, and remained cloudy after 12 hours.
実施例1及び2の結果より、(C)成分の塩酸を混合する前に急冷却することにより顕著に微細な脂肪酸のナノ粒子が得られることが分かる。 From the results of Examples 1 and 2, it can be seen that significantly fine fatty acid nanoparticles can be obtained by rapid cooling before mixing the hydrochloric acid of component (C).
実施例2〜4の結果より、(B)成分の界面活性剤の配合量が多いほど微細な脂肪酸のナノ粒子が得られることが分かる。 From the result of Examples 2-4, it turns out that the nanoparticle of a fine fatty acid is obtained, so that there are many compounding quantities of (B) component surfactant.
実施例2及び8の結果より、脂肪酸塩をカリウム塩にする方がナトリウム塩にするよりも微細な脂肪酸のナノ粒子が得られることが分かる。 From the results of Examples 2 and 8, it is understood that finer fatty acid nanoparticles can be obtained when the fatty acid salt is made of potassium salt than when it is made of sodium salt.
実施例2及び比較例2の結果より、有機溶剤のエタノールが存在することで脂肪酸の粒子径が大きくなると共に、安定性も著しく悪化することが分かる。 From the results of Example 2 and Comparative Example 2, it can be seen that the presence of the organic solvent ethanol increases the particle size of the fatty acid and significantly deteriorates the stability.
本発明はナノ粒子の製造方法及びそのナノ粒子について有用である。 The present invention is useful for a method for producing nanoparticles and the nanoparticles.
Claims (7)
炭素数10〜36の脂肪酸及び/又は脂肪酸塩である(A)成分の水溶液と、界面活性剤である(B)成分と、を混合する工程1と、
前記工程1で得られた液と、酸である(C)成分及び/又は2価〜3価の金属塩である(D)成分と、を混合する工程2と、
を含むナノ粒子の製造方法。 A method of producing nanoparticles by preparing a nanoparticle dispersion in the absence of an organic solvent,
Step 1 of mixing an aqueous solution of component (A) that is a fatty acid and / or fatty acid salt having 10 to 36 carbon atoms and component (B) that is a surfactant;
Step 2 of mixing the liquid obtained in Step 1 above with the component (C) that is an acid and / or the component (D) that is a divalent to trivalent metal salt;
The manufacturing method of the nanoparticle containing this.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008332780A JP5241480B2 (en) | 2008-12-26 | 2008-12-26 | Method for producing nanoparticles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008332780A JP5241480B2 (en) | 2008-12-26 | 2008-12-26 | Method for producing nanoparticles |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012134324A Division JP5406962B2 (en) | 2012-06-14 | 2012-06-14 | Method for producing nanoparticles |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010149087A true JP2010149087A (en) | 2010-07-08 |
JP5241480B2 JP5241480B2 (en) | 2013-07-17 |
Family
ID=42568787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008332780A Expired - Fee Related JP5241480B2 (en) | 2008-12-26 | 2008-12-26 | Method for producing nanoparticles |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5241480B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114524896A (en) * | 2021-12-20 | 2022-05-24 | 南京亘闪生物科技有限公司 | Preparation method of microsphere with wrinkled surface |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5144002B2 (en) * | 1974-09-20 | 1976-11-26 | ||
JPS5812267B2 (en) * | 1979-04-04 | 1983-03-07 | ヘミツシエ・ヴエルケ・ミユンヘン・オツト−・ベルロツヘルゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Manufacturing method of metal settsuken |
JPS59219400A (en) * | 1983-05-28 | 1984-12-10 | ミヨシ油脂株式会社 | Water dispersion of metal soap |
JPH01299247A (en) * | 1988-05-28 | 1989-12-04 | Nippon Oil & Fats Co Ltd | Continuous production of metal soap |
JPH02215743A (en) * | 1989-02-15 | 1990-08-28 | Sannopuko Kk | Production of aqueous dispersion of carboxylic acid salt |
JPH11309366A (en) * | 1998-04-28 | 1999-11-09 | Sannopuko Kk | Dispersion of fatty acid metal salt fine particle |
JPH11349591A (en) * | 1998-06-10 | 1999-12-21 | Fuji Photo Film Co Ltd | Preparation of fatty acid silber salt and thermally developable photosensitive material |
JP2005306972A (en) * | 2004-04-20 | 2005-11-04 | Sanyo Chem Ind Ltd | Fatty acid metal salt nano fine particle and the dispersion |
JP2008297233A (en) * | 2007-05-30 | 2008-12-11 | Sakai Chem Ind Co Ltd | Fine particulate metal soap and method for producing the same |
-
2008
- 2008-12-26 JP JP2008332780A patent/JP5241480B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5144002B2 (en) * | 1974-09-20 | 1976-11-26 | ||
JPS5812267B2 (en) * | 1979-04-04 | 1983-03-07 | ヘミツシエ・ヴエルケ・ミユンヘン・オツト−・ベルロツヘルゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Manufacturing method of metal settsuken |
JPS59219400A (en) * | 1983-05-28 | 1984-12-10 | ミヨシ油脂株式会社 | Water dispersion of metal soap |
JPH01299247A (en) * | 1988-05-28 | 1989-12-04 | Nippon Oil & Fats Co Ltd | Continuous production of metal soap |
JPH02215743A (en) * | 1989-02-15 | 1990-08-28 | Sannopuko Kk | Production of aqueous dispersion of carboxylic acid salt |
JPH11309366A (en) * | 1998-04-28 | 1999-11-09 | Sannopuko Kk | Dispersion of fatty acid metal salt fine particle |
JPH11349591A (en) * | 1998-06-10 | 1999-12-21 | Fuji Photo Film Co Ltd | Preparation of fatty acid silber salt and thermally developable photosensitive material |
JP2005306972A (en) * | 2004-04-20 | 2005-11-04 | Sanyo Chem Ind Ltd | Fatty acid metal salt nano fine particle and the dispersion |
JP2008297233A (en) * | 2007-05-30 | 2008-12-11 | Sakai Chem Ind Co Ltd | Fine particulate metal soap and method for producing the same |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114524896A (en) * | 2021-12-20 | 2022-05-24 | 南京亘闪生物科技有限公司 | Preparation method of microsphere with wrinkled surface |
CN114524896B (en) * | 2021-12-20 | 2024-05-24 | 南京亘闪生物科技有限公司 | Preparation method of surface fold microsphere |
Also Published As
Publication number | Publication date |
---|---|
JP5241480B2 (en) | 2013-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008127327A (en) | Nano-emulsion and cosmetic product compounded therewith | |
JP5320016B2 (en) | Topical skin preparation | |
JP5521979B2 (en) | Oral composition and method for stabilizing oral composition containing many oil components | |
JP2022509092A (en) | A composition for stabilizing a sparingly soluble component and a cosmetic composition containing the same. | |
JP5406962B2 (en) | Method for producing nanoparticles | |
JP5241480B2 (en) | Method for producing nanoparticles | |
JP5498769B2 (en) | Method for producing lipid-soluble drug-encapsulating nanoparticles | |
Cho et al. | Nano-emulsion formed with phospholipid-nonionic surfactant mixtures and its stability | |
JP2008120756A (en) | Emulsified skin external preparation containing powder | |
JP5086612B2 (en) | Emulsified skin external preparation containing hydroxyapatite-treated powder | |
JP4920276B2 (en) | Noble metal colloid-encapsulating lamella structure, dispersion thereof, cosmetic containing the same, and method for producing the dispersion | |
EP3743038B1 (en) | Process for making transparent nanoemulsions comprising lauric oil | |
JP2003267830A (en) | Liquid cosmetic | |
JP2003183692A (en) | Unsaturated fatty acid-containing fat powder | |
JP6411050B2 (en) | Liposomes and cosmetics containing the same | |
JP5964048B2 (en) | Emulsified composition | |
JP4960004B2 (en) | Ubidecalenone-containing cosmetic in vesicle dispersion dosage form | |
JP2008195676A (en) | Transparent cosmetic | |
EP3743037B1 (en) | Transparent nanoemulsions comprising lauric oil | |
EP2272488B1 (en) | Vesicle and cosmetic containing the same | |
JP2010241795A (en) | Pearl-like composition and cosmetic including the composition | |
JP2018076309A (en) | Nanoemulsion composition and cosmetic or external preparation containing the same | |
JP2010006739A (en) | Emulsified cosmetic | |
JP2017186280A (en) | Ursolic acid-containing liposome dispersion liquid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110906 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120131 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120406 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120614 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130319 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130402 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160412 Year of fee payment: 3 |
|
R151 | Written notification of patent or utility model registration |
Ref document number: 5241480 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160412 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |